2025 Annual Meeting | S5 - Updates on Amyotrophic Lateral Sclerosis
Program Materials Program Evaluations
| 03:30 PM - 03:42 PM PDT | Speaker |
2025 Sheila Essey Award: An Award for ALS Research: This award recognizes an individual who has made significant research contributions in the search for the cause, prevention of, and cure for amyotrophic lateral sclerosis (ALS)
Christopher J. McDermott, MBChB, FRCP, PhD |
| 03:42 PM - 03:54 PM PDT | Speaker |
2025 Sheila Essey Award: An Award for ALS Research: This award recognizes an individual who has made significant research contributions in the search for the cause, prevention of, and cure for amyotrophic lateral sclerosis (ALS)
Neil A. Shneider, MD, PhD |
| 03:54 PM - 04:06 PM PDT | Abstract |
003 - RAG-17, a Novel siRNA Therapy for SOD1-ALS: Safety and Preliminary Efficacy from a First-in-human Trial
weiqi chen, MD |
| 04:06 PM - 04:18 PM PDT | Abstract |
004 - Modeling the Human Corticospinal Tract-on-a-Chip
Andriana Charalampopoulou, MD |
| 04:18 PM - 04:30 PM PDT | Abstract |
005 - Altered Hypothalamic Functional Connectivity in Amyotrophic Lateral Sclerosis
Fabiola Freri, psychologist |
| 04:30 PM - 04:42 PM PDT | Abstract |
006 - Frequency and Predictors of Cognitive Deterioration in Amyotrophic Lateral Sclerosis: A Population-based Longitudinal Study
Maurizio Grassano, MD |
| 04:42 PM - 04:54 PM PDT | Abstract |
007 - Effect of Degree of Caloric Imbalance on ALS Disease Progression
Syed M. Jafri |
| 05:06 PM - 05:18 PM PDT | Abstract |
009 - Glymphatic Dysfunction in Clinical Phenotypes of Motor Neuron Disease
Ilaria Bottale, MD |
| 05:18 PM - 05:30 PM PDT | Abstract |
010 - Pridopidine for the Treatment of ALS–Improvements in the Subgroup of Definite, Probable, and Early (<18mo from Onset) Subjects in the Phase 2 Healey ALS Platform Trial
Merit E. Cudkowicz, MD, MSC, FAAN |
| James P. Orengo, MD, PhD | Dr. Orengo has nothing to disclose. |
| Dominic A. Ferrey, MD | Dr. Ferrey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Ferrey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Argenx. |
| Christopher J. McDermott, MBChB, FRCP, PhD | The institution of Dr. McDermott has received research support from NIHR. The institution of Dr. McDermott has received research support from MND Association. The institution of Dr. McDermott has received research support from LifeArc. The institution of Dr. McDermott has received research support from Verge. The institution of Dr. McDermott has received research support from PTC. |
| Neil A. Shneider, MD, PhD | Dr. Shneider has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alnylam. Dr. Shneider has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Shneider has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ProJenX. Dr. Shneider has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Regeneron. Dr. Shneider has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for GLG. Dr. Shneider has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Guidepoint. The institution of Dr. Shneider has received research support from Merck Sharp & Dohme. The institution of Dr. Shneider has received research support from National Institutes of Health. The institution of Dr. Shneider has received research support from ALS Association. The institution of Dr. Shneider has received research support from DoD/CDMRP - ALSRP. The institution of Dr. Shneider has received research support from Target ALS. The institution of Dr. Shneider has received research support from Ionis Pharmaceutical. The institution of Dr. Shneider has received research support from Cellenkos. |
| Adriano Chio, MD, FAAN | Dr. Chio has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cytokinetics. Dr. Chio has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mitsubishi. Dr. Chio has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Chio has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Corcept. |
| Francesca Palumbo | Dr. Palumbo has nothing to disclose. |
| Cristina Moglia | Cristina Moglia has nothing to disclose. |
| Umberto Manera, MD | Dr. Manera has nothing to disclose. |
| Maurizio Grassano, MD | Dr. Grassano has received research support from American Brain Foundation, ALS Association and 好色先生. |
| Rosario Vasta, MD | Dr. Vasta has nothing to disclose. |
| Gabriele Mora, MD | Dr. Mora has nothing to disclose. |
| Antonio Canosa | Antonio Canosa has nothing to disclose. |
| Barbara Iazzolino | Barbara Iazzolino has nothing to disclose. |
| Andrea Calvo, MD, PhD, FAAN | Dr. Calvo has nothing to disclose. |
| Rachel Thompson | Miss Thompson has nothing to disclose. |
| Muhannad Seyam, MD | Dr. Seyam has nothing to disclose. |
| Joan Skelly | Joan Skelly has nothing to disclose. |
| Jiayi Luo | Ms. Luo has nothing to disclose. |
| Syed M. Jafri | Mr. Jafri has nothing to disclose. |
| Waqar Waheed, MD, MBBS | Dr. Waheed has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. |
| Edward J. Kasarskis, MD, PhD, FAAN | The institution of Dr. Kasarskis has received research support from Healey Platform Trial Group. The institution of Dr. Kasarskis has received research support from Amylyx . The institution of Dr. Kasarskis has received research support from Alexion. The institution of Dr. Kasarskis has received research support from Woolsey . Dr. Kasarskis has a non-compensated relationship as a Director of ALSA-supported clinic at the University of Kentucky with ALS Association that is relevant to AAN interests or activities. |
| Rup Tandan, MD, FRCP, FAAN | Dr. Tandan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Tandan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Apellis. Dr. Tandan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Amylyx. The institution of Dr. Tandan has received research support from Alexion. The institution of Dr. Tandan has received research support from Apellis. The institution of Dr. Tandan has received research support from Cytokinetics. |
| Margo Nolan, BA | Miss Nolan has nothing to disclose. |
| Jinyi Ye | The institution of Dr. ye has received research support from Ractigen Therapeutics, Suzhou, China. |
| Lingling Jiang, PhD | Dr. Jiang has nothing to disclose. |
| ling wang, MS | Miss wang has nothing to disclose. |
| Hui Qu, master of medicine | The institution of Mr. Qu has received research support from Ractigen Therapeutics, Suzhou,China. |
| Xuan Wang, PhD | The institution of Dr. Wang has received research support from Ractigen Therapeutics, Suzhou,China. |
| Hui Qu, master of medicine | Mr. Qu has received research support from Ractigen Therapeutics, Suzhou,China. |
| xiaoling liao, MD | Dr. liao has received research support from Ractigen Therapeutics, Suzhou,China. |
| xuejiao zhou, Bachelor of Nursing | The institution of Miss zhou has received research support from Ractigen Therapeutics, Suzhou,China. |
| Shawn Zhang, MD | Ms. Zhang has nothing to disclose. |
| Moorim Kang, PhD | Dr. Kang has nothing to disclose. |
| Long-Cheng Li, MD | Dr. Li has stock in Ractigen Therapeutics. Dr. Li has received intellectual property interests from a discovery or technology relating to health care. |
| weiqi chen, MD | Dr. chen has received research support from Ractigen Therapeutics, Suzhou,China. The institution of Dr. chen has received research support from Beijing Nova Program . |
| Yilong Wang, MD | The institution of Dr. Wang has received research support from Ractigen Therapeutics, Suzhou, China. The institution of Dr. Wang has received research support from the National Natural Science Foundation of China. The institution of Dr. Wang has received research support from Capital's Funds for Health Improvement and Research. The institution of Dr. Wang has received research support from National Key R&D Program of China. The institution of Dr. Wang has received research support from Beijing Laboratory of Oral Health. The institution of Dr. Wang has received research support from Beijing Municipal Science & Technology Commission. The institution of Dr. Wang has received research support from Noncommunicable Chronic Diseases-National Science and Technology Major Project . |
| Arens Taga, MD | Dr. Taga has nothing to disclose. |
| Andriana Charalampopoulou, MD | Ms. Charalampopoulou has nothing to disclose. |
| Arun Venkatesan, MD, PhD | Dr. Venkatesan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen Pharmaceuticals. The institution of Dr. Venkatesan has received research support from NIH. The institution of Dr. Venkatesan has received research support from MSRCF. The institution of Dr. Venkatesan has received research support from U.S. DOD. |
| Christa Habela, MD | The institution of Dr. Habela has received research support from NINDS. Dr. Habela has received publishing royalties from a publication relating to health care. |
| Nicholas J. Maragakis, MD, FAAN | Dr. Maragakis has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UptoDate. Dr. Maragakis has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Apellis Pharmaceuticals. Dr. Maragakis has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amylyx. An immediate family member of Dr. Maragakis has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for National Basketball Association. Dr. Maragakis has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Akava. An immediate family member of Dr. Maragakis has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for Johns Hopkins Howard County Medical Center. Dr. Maragakis has stock in Akava. The institution of Dr. Maragakis has received research support from NIH/NINDS. The institution of Dr. Maragakis has received research support from Department of Defense. The institution of Dr. Maragakis has received research support from Maryland Stem Cell Research Fund. Dr. Maragakis has received intellectual property interests from a discovery or technology relating to health care. |
| Pashtun-Poh Shahim, MD, PhD | Pashtun-Poh Shahim has nothing to disclose. |
| Abdullah Z. Alqahtani, MD | Dr. Alqahtani has nothing to disclose. |
| Angela Kokkinis | Angela Kokkinis has nothing to disclose. |
| Christopher Grunseich, MD | Dr. Grunseich has nothing to disclose. |
| Alice B. Schindler, MS, CGC | Ms. SCHINDLER has nothing to disclose. |
| Elizabeth Howe | Ms. Howe has nothing to disclose. |
| George G. Harmison, MS | Mr. Harmison has nothing to disclose. |
| Jahan Misra, BS | Mr. Misra has received personal compensation in the range of $50,000-$99,999 for serving as a Post-bac IRTA with National Institutes of Health. |
| Narjis Kazmi, MPH | Miss Kazmi has nothing to disclose. |
| Mmasinachi M. Ezuma-Ngwu, NIH Post Bacc Research Fellow | Miss Ezuma-Ngwu has nothing to disclose. |
| Ilaria Bottale, MD | Dr. Bottale has nothing to disclose. |
| Edoardo G. Spinelli, MD | Dr. Spinelli has nothing to disclose. |
| Silvia Basaia | Silvia Basaia has nothing to disclose. |
| Alma Ghirelli | No disclosure on file |
| Francesca Orlandi | No disclosure on file |
| Tommaso Russo, MD | Dr. Russo has nothing to disclose. |
| Elisa Canu | The institution of Elisa Canu has received research support from Italian Ministry of Health . |
| Veronica Castelnovo, MSc | Dr. Castelnovo has nothing to disclose. |
| Paride Schito | Paride Schito has nothing to disclose. |
| Yuri Falzone | Yuri Falzone has nothing to disclose. |
| Federica Agosta | Federica Agosta has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Philips. Federica Agosta has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier INC. |
| Massimo Filippi, MD, FAAN | Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sanofi. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion, Biogen, Bristol-Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi-Genzyme, Takeda. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and TEVA. Dr. Filippi has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Nature. The institution of Dr. Filippi has received research support from Biogen Idec, Merck-Serono, Novartis, Roche, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla. |
| Fabiola Freri, psychologist | Miss Freri has nothing to disclose. |
| Francesco Roselli | No disclosure on file |
| Hans-Peter Müller | No disclosure on file |
| Jan Kassubek, MD | Prof. Kassubek has nothing to disclose. |
| Albert C. Ludolph, MD | Dr. Ludolph has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Ludolph has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Ludolph has received personal compensation in the range of $0-$499 for serving as a Consultant for FundaMental Pharma . Dr. Ludolph has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lilly. Dr. Ludolph has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Zambon . Dr. Ludolph has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Ludolph has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche Pharma. Dr. Ludolph has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Ludolph has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alector. Dr. Ludolph has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amylyx. Dr. Ludolph has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biologix FZCo.. Dr. Ludolph has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. Dr. Ludolph has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Teva. Dr. Ludolph has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. Dr. Ludolph has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. Dr. Ludolph has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Zambon. |
| Michal Geva | Michal Geva has received personal compensation for serving as an employee of Prilenia Therapeutics. Michal Geva has received intellectual property interests from a discovery or technology relating to health care. |
| Jeremy M. Shefner, MD, PhD, FAAN | Dr. Shefner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amylyx. Dr. Shefner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Uniqure. Dr. Shefner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Clene. Dr. Shefner has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Cytokinetics. Dr. Shefner has received personal compensation in the range of $0-$499 for serving as a Consultant for Mitsubishi Tanabe Pharma America. Dr. Shefner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for annexon. Dr. Shefner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Shefner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Dr. Shefner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurosense. Dr. Shefner has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Neuvivo. Dr. Shefner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Nura BIo. Dr. Shefner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Prilenia. Dr. Shefner has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for swanbio. Dr. Shefner has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for vertex. Dr. Shefner has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. Dr. Shefner has received personal compensation in the range of $50,000-$99,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for UpToDate. The institution of Dr. Shefner has received research support from NIH. The institution of Dr. Shefner has received research support from Mitsubishi Tanabe Pharma America. The institution of Dr. Shefner has received research support from Amylyx. The institution of Dr. Shefner has received research support from BIogen. The institution of Dr. Shefner has received research support from Cytokinetics. The institution of Dr. Shefner has received research support from IONIS. The institution of Dr. Shefner has received research support from Healey Center for ALS. Dr. Shefner has received personal compensation in the range of $500-$4,999 for serving as a grant review chair with DOD- General Dynamics. |
| Bjorn E. Oskarsson, MD, FAAN | Dr. Oskarsson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amylyx. The institution of Dr. Oskarsson has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Oskarsson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AnnJi. The institution of Dr. Oskarsson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mitsubishi. Dr. Oskarsson has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Tsumura. The institution of Dr. Oskarsson has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MediciNova. The institution of Dr. Oskarsson has received research support from Biogen. The institution of Dr. Oskarsson has received research support from Medicinova. The institution of Dr. Oskarsson has received research support from Cytokinetics. The institution of Dr. Oskarsson has received research support from Calico. The institution of Dr. Oskarsson has received research support from Mitsubishi. The institution of Dr. Oskarsson has received research support from Tsumura. The institution of Dr. Oskarsson has received research support from Sanofi. The institution of Dr. Oskarsson has received research support from AZTherapeutics. The institution of Dr. Oskarsson has received research support from Orion. The institution of Dr. Oskarsson has received research support from Esaii. |
| Rachel G. Lichtenstein, PhD | Dr. Lichtenstein has nothing to disclose. |
| May Meltzer, PhD | Mrs. Meltzer has nothing to disclose. |
| Yael Cohen | Yael Cohen has nothing to disclose. |
| Randal Hand | Dr. Hand has received personal compensation for serving as an employee of Prilenia Therapeutics. |
| Kelly Chen | Kelly Chen has received personal compensation for serving as an employee of Prilenia Therapeutics. |
| Melanie Leitner, PhD | Dr. Leitner has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Prilenia. Dr. Leitner has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for ALS Investment Fund. Dr. Leitner has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Fundamental Pharma. Dr. Leitner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Caraway. Dr. Leitner has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Affinia Therapeutics. Dr. Leitner has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Jannsen. Dr. Leitner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Tolerion/Alpha-5 Integrin. Dr. Leitner has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Verge Genomics. Dr. Leitner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Tranquis. Dr. Leitner has stock in Bristol Myers Squibb. Dr. Leitner has stock in Editas. Dr. Leitner has stock in Provention Bio. Dr. Leitner has stock in Sanofi. Dr. Leitner has stock in Vertex. Dr. Leitner has stock in GSK. Dr. Leitner has stock in Eledon. Dr. Leitner has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant with ALS Finding a Cure. Dr. Leitner has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant with Charley's Fund. |
| Sabrina Paganoni, MD, PhD | Dr. Paganoni has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cytokinetics. Dr. Paganoni has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Jannsen. Dr. Paganoni has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Arrowhead. Dr. Paganoni has received personal compensation in the range of $0-$499 for serving as a Consultant for Sola. Dr. Paganoni has received personal compensation in the range of $0-$499 for serving as a Consultant for Frequency Therapeutics. The institution of Dr. Paganoni has received research support from Amylyx. The institution of Dr. Paganoni has received research support from Revalesio. The institution of Dr. Paganoni has received research support from Alector. The institution of Dr. Paganoni has received research support from UCB. The institution of Dr. Paganoni has received research support from Biohaven. The institution of Dr. Paganoni has received research support from Clene. The institution of Dr. Paganoni has received research support from Prilenia. The institution of Dr. Paganoni has received research support from Seelos. The institution of Dr. Paganoni has received research support from Calico. The institution of Dr. Paganoni has received research support from Denali. The institution of Dr. Paganoni has received research support from Anelixis. The institution of Dr. Paganoni has received research support from Cytokinetics. |
| Merit E. Cudkowicz, MD, MSC, FAAN | Dr. Cudkowicz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for biogen. Dr. Cudkowicz has received personal compensation in the range of $0-$499 for serving as a Consultant for cytokinetics. Dr. Cudkowicz has received personal compensation in the range of $0-$499 for serving as a Consultant for immunitypharm. Dr. Cudkowicz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for transposon. Dr. Cudkowicz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Quralis. Dr. Cudkowicz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Regeneron. Dr. Cudkowicz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for vectorY. Dr. Cudkowicz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for inflectis. Dr. Cudkowicz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for novartis. Dr. Cudkowicz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ono. Dr. Cudkowicz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for otsuka. Dr. Cudkowicz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for coya. Dr. Cudkowicz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ac immune. Dr. Cudkowicz has received personal compensation in the range of $0-$499 for serving as a Consultant for pontifax. Dr. Cudkowicz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Inflectis. Dr. Cudkowicz has received personal compensation in the range of $0-$499 for serving as a Consultant for ab science. Dr. Cudkowicz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for aclipse. Dr. Cudkowicz has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Locust Walk. Dr. Cudkowicz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pasithea. Dr. Cudkowicz has received personal compensation in the range of $50,000-$99,999 for serving as an officer or member of the Board of Directors for Praxis Precision Medicine. Dr. Cudkowicz has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Annals of Neurology . The institution of Dr. Cudkowicz has received research support from NINDS. The institution of Dr. Cudkowicz has received research support from ALSFAC. The institution of Dr. Cudkowicz has received research support from UCB ra. The institution of Dr. Cudkowicz has received research support from Biohaven. The institution of Dr. Cudkowicz has received research support from Clene nanomedicine. The institution of Dr. Cudkowicz has received research support from prilenia. The institution of Dr. Cudkowicz has received research support from ALS one. The institution of Dr. Cudkowicz has received research support from Seelos. The institution of Dr. Cudkowicz has received research support from Calico. The institution of Dr. Cudkowicz has received research support from denali. The institution of Dr. Cudkowicz has received research support from ITB. The institution of Dr. Cudkowicz has received research support from PharmAust. The institution of Dr. Cudkowicz has received research support from woolsley. Dr. Cudkowicz has received research support from lilly. The institution of Dr. Cudkowicz has received research support from J& J. Dr. Cudkowicz has received publishing royalties from a publication relating to health care. |
| Michael Hayden | Michael Hayden has received personal compensation for serving as an employee of Prilenia Therapeutics. Michael Hayden has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for CAMP4. Michael Hayden has received personal compensation in the range of $50,000-$99,999 for serving as an officer or member of the Board of Directors for AbCellera Biologics Inc.. Michael Hayden has received personal compensation in the range of $50,000-$99,999 for serving as an officer or member of the Board of Directors for Ionis Pharmaceuticals . Michael Hayden has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for 89 Bio. Michael Hayden has received personal compensation in the range of $50,000-$99,999 for serving as an officer or member of the Board of Directors for Oxford Biomedica . Michael Hayden has stock in Ionis Pharmaceuticals. Michael Hayden has stock in AbCellera Biologics Inc.. Michael Hayden has stock in 89 Bio. The institution of Michael Hayden has received research support from Canadian Institutes of Health Research. The institution of Michael Hayden has received research support from National Research Council Canada. The institution of Michael Hayden has received research support from Huntington Society of Canada. The institution of Michael Hayden has received research support from Bev Hartig Huntington Disease Foundation. Michael Hayden has received intellectual property interests from a discovery or technology relating to health care. Michael Hayden has received intellectual property interests from a discovery or technology relating to health care. Michael Hayden has received intellectual property interests from a discovery or technology relating to health care. Michael Hayden has received intellectual property interests from a discovery or technology relating to health care. Michael Hayden has received intellectual property interests from a discovery or technology relating to health care. Michael Hayden has received intellectual property interests from a discovery or technology relating to health care. Michael Hayden has received intellectual property interests from a discovery or technology relating to health care. Michael Hayden has received intellectual property interests from a discovery or technology relating to health care. Michael Hayden has received intellectual property interests from a discovery or technology relating to health care. Michael Hayden has received intellectual property interests from a discovery or technology relating to health care. |
| Yuesong Pan, PhD | Dr. pan has nothing to disclose. |